Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin class switch recombination (CSR), also known as antibody class switching or isotype switching, is a biological process that occurs in activated B cells, allowing them to change the class of antibody they produce (from IgM and IgD to IgG, IgA, or IgE) without altering the antigen specificity. This process involves a deletional recombination event between DNA switch (S) regions that are located upstream of the immunoglobulin heavy chain constant region genes. CSR is initiated by activation-induced cytidine deaminase (AID), which deaminates cytosines in S regions, leading to DNA breaks and recombination facilitated by DNA repair enzymes. The process is essential for a robust and tailored humoral immune response, enabling antibodies to interact with different effector molecules to combat pathogens more effectively. Dysregulation of CSR can contribute to immunodeficiencies or autoimmunity, but it is not itself a direct therapeutic target as it is a biological mechanism rather than a single molecule, receptor, or enzyme[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin class switch recombination (CSR).